Every 8-K that AUTOLUS THERAPEUTICS PLC (AUTL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AUTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUTL filings page.
Autolus Therapeutics plc reported strong second-quarter 2026 growth driven by its CD19 CAR T therapy AUCATZYL. Net product revenue was $45.7 million for the quarter, up from $20.9 million a year earlier, and 1H 2026 net product revenue was $71.9 million. Gross margin improved sharply to 55% in Q2 2026 from 6% in Q1 2026, reflecting higher volumes and cost-efficiency initiatives. Full-year 2026 AUCATZYL net product revenue guidance was raised to $140–$150 million from $120–$135 million. Loss from operations narrowed to $43.8 million, with net loss at $39.1 million, or $(0.15) per share. Liquidity remained solid with $201.6 million in cash, cash equivalents and marketable securities at June 30, 2026, and a new five-year, interest-only senior credit facility of up to $250 million, including $75 million funded and an additional $25 million available. A prior 13% workforce reduction is expected to lower annual operating expenses by about $15 million starting in 2027, supporting a stated path toward profitability in the adult r/r B-ALL business while Autolus advances multiple obe-cel trials in lupus, pediatric ALL, multiple sclerosis and amyloidosis.
Autolus Therapeutics raised its full-year 2026 guidance for AUCATZYL net product revenue to $140 million–$150 million, up from $120 million–$135 million. Management reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million, with AUCATZYL sales increasing about 70% over Q1 2026 and more than 100% versus Q2 2025. Year-to-date gross margin reached approximately 35% for the first half of 2026, compared with a negative gross margin of about 20% in the second half of 2025.
The company entered into a five-year, interest-only senior credit facility with Perceptive Advisors for up to $250 million in aggregate principal amount. An initial $75 million was funded on July 30, 2026, with an additional $25 million available at Autolus’ option for six months and up to $150 million more in later tranches upon revenue milestones. The facility bears interest at one-month SOFR (with a 3.50% floor) plus 7.25%. Autolus also issued Perceptive a warrant to purchase up to 3.5 million ADSs at an exercise price of $1.9314 per ADS. Based on anticipated AUCATZYL revenues and this financing, the company expects its cash, cash equivalents and marketable securities to fund operations into the second quarter of 2028.
Autolus Therapeutics plc entered into a senior secured notes facility of up to $250.0 million with Perceptive Credit Holdings V, LP. On July 30, 2026 it issued $75.0 million of Tranche 1 Notes, with up to $175.0 million available in three additional tranches: $25.0 million through January 30, 2027 and two $75.0 million tranches contingent on Consolidated Net Revenue levels before July 31, 2028 and January 31, 2030.
The notes mature on July 30, 2031 and bear interest, paid monthly, at 6.75%–7.25% above the greater of one‑month term SOFR or 3.50%, with a possible 4.00% default step‑up. Obligations are guaranteed by key subsidiaries and secured by a first‑priority lien on substantially all assets, and include financial covenants such as maintaining a Minimum Liquidity Amount between $12.5 million and $50.0 million and specified Consolidated Net Revenue levels.
In connection with the financing, Autolus issued Perceptive a warrant for up to 3,500,000 ADSs at an exercise price of $1.9314 per ADS, a 25% premium to the 30‑day volume weighted average price, and will issue additional warrants for up to 2,500,000 ADSs with each of Tranche 3 and Tranche 4. All warrants expire on July 30, 2036, may be exercised on a cashless basis, and benefit from resale registration rights.
Autolus Therapeutics plc reported the results of its 2026 Annual General Meeting held on June 29, 2026. Shareholders approved all six ordinary resolutions presented at the meeting.
They received and adopted the 2025 Annual Report and Accounts, with 165,846,326 votes for and 2,895,344 against. The directors’ remuneration report was approved with 156,192,216 votes for and 12,502,946 against. Ernst & Young LLP (US) was appointed as auditors, receiving 165,871,368 votes in favor and 2,872,225 against.
Shareholders also re-elected three directors. Mr. M Bonney was re-elected with 165,491,394 votes for and 3,312,126 against. Dr. E Leiderman was re-elected with 165,741,204 votes for and 3,063,838 against. Mr. R W Azelby was re-elected with 162,133,091 votes for and 6,671,776 against.
Autolus Therapeutics plc has furnished its UK Annual Report and Accounts for the year ended December 31, 2025 and the notice of its annual general meeting, to be held on June 29, 2026, to shareholders. These materials are provided as exhibits and are not incorporated by reference into other securities filings unless expressly stated.
Citibank, as depositary for Autolus’ American Depositary Shares, is mailing voting materials to ADS holders of record as of May 27, 2026 so they can instruct how to vote the underlying ordinary shares. ADS holders are reminded that practical and legal limits may affect the depositary’s ability to execute all instructions.
The UK Annual Report outlines Autolus’ transition to an early commercial-stage biopharmaceutical company, highlighted by US, UK and EU approvals for its CD19 CAR T cell therapy AUCATZYL (obe-cel) in adult relapsed or refractory B‑cell acute lymphoblastic leukaemia and initial launches in the United States and United Kingdom.
Autolus Therapeutics reported strong commercial momentum for AUCATZYL in the first quarter of 2026, with net product revenue rising to $26.2 million from $9.0 million a year earlier. This shift supported the company’s first positive gross margin for its acute lymphoblastic leukemia business.
Despite this progress, Autolus remains loss-making, with a Q1 2026 net loss of $71.6 million and basic and diluted net loss per share of $(0.27). The company is executing a cost reduction plan, including a workforce reduction of about 13% and expects annualized operating expense savings of roughly $15 million from 2027, after about $8 million in restructuring charges. Management reaffirmed 2026 AUCATZYL net product revenue guidance of $120–$135 million and expects existing cash, cash equivalents and marketable securities of $229.4 million as of March 31, 2026 to fund operations into Q4 2027.
Autolus Therapeutics plc is implementing a restructuring plan that includes a reduction in force affecting approximately 13% of its workforce, leading to estimated total restructuring charges of about $8 million, primarily for severance and related costs. The company expects to record a significant portion of these charges in the first half of 2026 and to substantially complete the workforce reduction by the third quarter of 2026.
Autolus projects that these actions will reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027. It confirmed financial guidance for full-year 2026 AUCATZYL net product revenue of $120 million to $135 million and, based on current plans, continues to expect its cash, cash equivalents and marketable securities to fund operations into the fourth quarter of 2027.
Autolus Therapeutics plc has changed its independent registered public accounting firm, dismissing Ernst & Young LLP (UK) and appointing Ernst & Young LLP (US) for the fiscal year ending December 31, 2026. The company states there were no disagreements with EY UK on accounting, disclosure, or audit matters and no reportable events, other than previously disclosed material weaknesses in internal control over financial reporting as of March 31, 2024. EY UK’s audit reports for the years ended December 31, 2025 and 2024 contained unmodified opinions, and EY UK has provided a letter to the SEC agreeing with the company’s description of the relationship.
Autolus Therapeutics plc furnished an investor presentation focused on its acute lymphoblastic leukemia (ALL) business and its CD19 CAR-T therapy AUCATZYL/obe-cel. The slides highlight the high unmet need in adult and pediatric relapsed/refractory B-ALL and position CAR-T as a potential curative option, especially for patients ineligible for transplant.
The presentation reviews FELIX trial data, real‑world ROCCA registry experience, and pediatric CATULUS Phase Ib results, emphasizing high response rates, low rates of severe CRS/ICANS, and manageable manufacturing timelines. Autolus outlines plans to broaden AUCATZYL’s use across age groups, move obe‑cel into frontline consolidation, and support pediatric regulatory expansion through ongoing and planned studies.
Autolus Therapeutics reported fourth-quarter and full-year 2025 results that reflect its first commercial year for AUCATZYL. Net product revenue reached $23.3 million in Q4 2025 and $74.3 million for the full year, driving total 2025 revenue to $75.4 million including license revenue.
Autolus projects 2026 AUCATZYL net product revenue of $120 million to $135 million and expects to achieve a shift to positive gross margin in 2026 as volumes rise and manufacturing efficiency improves. Cost of sales were $96.4 million in 2025, research and development expenses $117.7 million, and selling, general and administrative expenses $131.9 million, resulting in a full-year net loss of $287.5 million.
Cash, cash equivalents and marketable securities totaled $300.7 million as of December 31, 2025, down from $588.0 million a year earlier, and the company expects this funding, together with anticipated AUCATZYL revenue, to support operations into Q4 2027. Autolus also highlighted advancing trials of obe-cel in pediatric B-ALL, lupus nephritis, progressive multiple sclerosis and systemic lupus erythematosus with multiple data readouts expected between year-end 2026 and 2028.
Autolus Therapeutics plc, through its wholly owned subsidiary Autolus Limited, entered into a 10-year Master Service Agreement with AGC Biologics S.p.A to manufacture and supply lentiviral vector, a key raw material for its CAR-T products for clinical and commercial use. This Agreement replaces the parties’ prior arrangement and sets general terms, with individual projects defined in separate work orders.
The Agreement is non-exclusive and can be terminated for default by either party, or by Autolus on notice subject to certain fees. Autolus has committed to purchase a minimum of 14 batches of lentiviral vector during the first two calendar years of the term, and a minimum value of EUR 25 million in products and services over the subsequent five-year period. AGC also receives a first right to negotiate new manufacturing activities related to Autolus’ obecabtagene autoleucel (obe-cel) product.
Autolus Therapeutics plc reported preliminary, unaudited net product revenue for its CAR-T therapy AUCATZYL (obe-cel). The company expects approximately $24 million of AUCATZYL net product revenue for the fourth quarter of 2025 and approximately $75 million for full year 2025. Based on current operating plans and anticipated AUCATZYL revenues, Autolus believes its cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027.
For 2026, Autolus anticipates AUCATZYL net product revenue in a range of $120 million to $135 million. The company also highlighted updates to its pipeline programs, including development of obe-cel in additional indications such as lupus nephritis and progressive multiple sclerosis, and reiterated plans to expand commercialization and market access, including in Europe. Final 2025 results are expected to be released in March 2026.
Autolus Therapeutics plc filed an 8-K announcing it furnished its financial results for the quarter ended September 30, 2025 and provided a corporate update. The results were furnished as Exhibit 99.1, and an updated corporate presentation was furnished as Exhibit 99.2; these materials are furnished, not filed.
The Board noted that Chief Financial Officer Rob Dolski resigned as principal accounting officer but remains CFO and Principal Financial Officer. Patrick McIlvenny was appointed Principal Accounting Officer effective November 7, 2025, with no additional compensation and no related-party or family relationships disclosed.
Autolus Therapeutics announced it has released its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) that it will use in a conference call; both exhibits are expressly noted as furnished rather than filed.
The 8-K clarifies that the information in the exhibits is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically stated. The form text does not include the underlying financial tables, revenue, expense or cash metrics, so detailed figures and operational commentary must be obtained from the attached Exhibit 99.1 and Exhibit 99.2.
Autolus Therapeutics (Nasdaq:AUTL) filed a Form 8-K reporting the results of its 26 June 2025 Annual General Meeting.
All seven ordinary resolutions passed, including:
- Adoption of the 2024 Annual Report (219.8 M for; 0.1 M against).
- Approval of the directors’ remuneration report (216.0 M for; 4.3 M against).
- Approval of the directors’ remuneration policy (203.4 M for; 16.9 M against).
- Re-appointment of Ernst & Young LLP as auditors (220.3 M for).
- Re-election of directors Dr R. Iannone and Dr R. Rao.
- Adoption of a new Employee Share Purchase Plan authorizing up to 3 million shares.